NCT03702725 2026-01-06
Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma
Alliance Foundation Trials, LLC.
Phase 1 Completed
Alliance Foundation Trials, LLC.
Sumitomo Pharma America, Inc.
Pharmacyclics Switzerland GmbH
Pharmacyclics LLC.